Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Zhejiang Jiuzhou Pharmaceutical Co., Ltd., commonly referred to as Jiuzhou, is a prominent player in the pharmaceutical preparation manufacturing industry, headquartered in China. Established in 1995, the company has made significant strides in developing high-quality pharmaceutical products, focusing on areas such as injectables, oral solid forms, and advanced drug delivery systems.
With a strong operational presence across various regions in China, Jiuzhou is recognised for its commitment to innovation and quality. The company’s core offerings include a diverse range of generic and proprietary medications, distinguished by their efficacy and safety profiles. Jiuzhou's dedication to research and development has positioned it as a leader in the market, achieving notable certifications and accolades that underscore its reputation for excellence in the pharmaceutical sector.
+7 vs industry average
Zhejiang Jiuzhou’s score of 49 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the most carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Zhejiang Jiuzhou, a Pharmaceutical Preparation Manufacturing company headquartered in China, reported Scope 1 emissions of 102,855 kg CO2e, Scope 2 market-based emissions of 198,868 kg CO2e, and Scope 3 emissions of 418,334,000 kg CO2e for 2024.
The company has set Science Based Targets initiative (SBTi) approved near-term targets. Zhejiang Jiuzhou is committed to reducing absolute Scope 1 and Scope 2 greenhouse gas emissions by 42.0% by 2030, from a 2024 base year. Additionally, the company aims to reduce absolute Scope 3 GHG emissions from purchased goods and services, and fuel- and energy-related activities by 25.0% within the same timeframe. These targets are consistent with reductions required to keep warming to 1.5°C.
2030
42% reduction in Scope 1
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. commits to reduce absolute scope 1 GHG emissions 42.0% by 2030 from a 2024 base year.
2030
42% reduction in Scope 2
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. commits to reduce absolute scope 2 GHG emissions 42.0% by 2030 from a 2024 base year.
2030
25% reduction in scope 3 upstream
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. also commits to reduce absolute scope 3 GHG emissions from purchased goods and services and fuel-…
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Common questions about Zhejiang Jiuzhou’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more